Arrowstreet Capital
CMPX icon

Arrowstreet Capital’s Compass Therapeutics CMPX Stock Holding History

Arrowstreet Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-210,249
Closed -$1.13M – 1883
2025
Q4 		$1.13M Buy
+210,249
New +$971K ﹤0.01% 1527

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Arrowstreet Capital's CMPX Position: Q1 2026 in Review

Arrowstreet Capital sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 210,249 shares — an estimated $1.13M sold.

Arrowstreet Capital first reported a position in CMPX in Q4 2025 and held it in 1 quarter. The position peaked at $1.13M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Arrowstreet Capital reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 210,249 Compass Therapeutics shares in Q1 2026, an estimated $1.13M.
  • Arrowstreet Capital first reported a position in Compass Therapeutics in Q4 2025 and held it in 1 quarter.
  • Arrowstreet Capital's Compass Therapeutics position peaked at $1.13M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.